Vimta's 33.82% margin beats healthcare peer median by 13 points
Standalone Q2FY27 operating profit was Rs 37.87 cr, while other income of Rs 2.90 cr was not the main source of pre-tax profit.
Filed 30 Oct 2026, 13:15 IST · Vimta Labs Ltd (VIMTALABS)
Key takeaways
- Vimta Labs reported a standalone operating margin of 33.82%, 13 percentage points above the 20.82% median for 38 Healthcare peers.
- Standalone net profit of Rs 20.61 cr was generated after Rs 12.87 cr of depreciation and a 25.11% tax rate.
- Management's presentation describes Vimta as number one in India in pharma analytical services and among the top three in food and environment testing.
Price around the results
Margin stands well above the healthcare peer set
Vimta Labs' standalone operating margin was 33.82%, putting it 13 percentage points above the 20.82% median of 38 Healthcare companies that have reported the quarter. That places Vimta among the higher-margin reporters in the sector, with no sequential or year-on-year comparison provided for this quarter.
Profit conversion was led by operating earnings
Operating profit of Rs 37.87 cr on revenue of Rs 111.98 cr indicates that the quarter's profit was primarily generated from operations. Other income of Rs 2.90 cr was small relative to pre-tax profit of Rs 27.52 cr, so reported earnings were not mainly built on non-operating income. Depreciation of Rs 12.87 cr and tax of Rs 6.91 cr reduced operating profit to net profit of Rs 20.61 cr.
Presentation highlights expansion and market positioning
Management said capacity expansions, service innovations, customer partnerships and cutting-edge technologies are core business strategies. The presentation also says the company is number one in India in pharma analytical services and ranks among the top three in food and environment testing.
Q2FY27 at a glance
Standalone figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 |
|---|---|
| Revenue | ₹112 cr |
| Other income | ₹3 cr |
| Expenses | ₹74 cr |
| Operating profit | ₹38 cr |
| Operating margin (%) | 33.82% |
| Interest | ₹0 cr |
| Depreciation | ₹13 cr |
| Profit before tax | ₹28 cr |
| Tax | ₹7 cr |
| Net profit | ₹21 cr |
| EPS (₹) | ₹4.61 |
Operating margin of 33.82% compares with a Healthcare sector median of 20.82% across 38 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Expansion
- The company lists capacity expansions among its core business strategies.
New initiatives
- The company identifies service innovations as a core business strategy.
- The company identifies customer partnerships as a core business strategy.
- The company identifies cutting-edge technologies among its core operational strategies.
Competition
- The company describes itself as number one in India in pharma analytical services.
- The company describes its food and environment testing business as among the top three in India.
What to watch
- Whether standalone operating margin remains near 33.82%.
- Whether other income stays contained relative to pre-tax profit of Rs 27.52 cr.
- Whether net profit continues to convert from operating profit of Rs 37.87 cr after depreciation of Rs 12.87 cr.